Marginal treatment benefit in anaplastic thyroid cancer

Cancer

Volumn 119, Issue 17, 2013, Pages 3133-3139

  Haymart, Megan R ^a   Banerjee, Mousumi ^b   Yin, Huiying ^b   Worden, Francis ^a   Griggs, Jennifer J ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c University of Michiga   (United States)

Author keywords

anaplastic thyroid cancer; cancer; survival; thyroid; treatment

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COMORBIDITY; FEMALE; HEALTH INSURANCE; HISPANIC; HUMAN; LOBECTOMY; MAJOR CLINICAL STUDY; MALE; NEGRO; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; SURVIVAL RATE; THYROIDECTOMY;

ANAPLASTIC THYROID CANCER; CANCER; SURVIVAL; THYROID; TREATMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84882695623     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28187     Document Type: Article

References (23)

1. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. www.seer.cancer.gov. Accessed November 1, 2011.
2. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A,. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103: 1330-1335.
3. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA,. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66: 321-330.
4. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001; 130: 1028-1034.
5. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001; 91: 2335-2342.
6. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011; 21: 25-30.
7. Kim TY, Kim KW, Jung TS, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck. 2007; 29: 765-772.
8. Gilliland FD, Hunt WC, Morris DM, Key CR,. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997; 79: 564-573.
9. Smallridge RC, Ain KB, Asa SL, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22: 1104-1139.
10. Bilimoria KY, Stewart AK, Winchester DP, Ko CY,. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15: 683-690.
11. American Joint Committee on Cancer. Comparison guide: cancer staging manual, fifth versus sixth edition. www.cancerstaging.org/products/ajccguide. pdf. Accessed November 1, 2012.
12. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011; 21: 1183-1189.
13. Chen J, Tward JD, Shrieve DC, Hitchcock YJ,. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol. 2008; 31: 460-464.
14. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002; 86: 1848-1853.
15. Kim JH, Leeper RD,. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer. 1983; 52: 954-957.
16. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S,. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994; 74: 1348-1354.
17. Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol. 2011; 101: 425-430.
18. Krieger N,. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992; 82: 703-710.
19. Smith TJ, Hillner BE,. Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small. Clin Cancer Res. 2010; 16: 5981-5986.
20. Kadakia KC, Moynihan TJ, Smith TJ, Loprinzi CL,. Palliative communications: addressing chemotherapy in patients with advanced cancer. Ann Oncol. 2012; 23 (suppl 3): 29-32.
21. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC,. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004; 22: 315-321.
22. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367: 1616-1625.
23. Wright AA, Mack JW, Kritek PA, et al. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer. 2010; 116: 4656-4663.